Viridian Therapeutics (VRDN) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of approximately -$1.04, reflecting ongoing R&D investments in thyroid eye disease (TED) pipeline.
• Consensus revenue forecast around $0.1 million, consistent with pre-commercial biotech stage.
• Cash position stood at $875 million end-2025, supporting runway through profitability pending approvals.
• Key focus: Updates on veligrotug BLA (PDUFA June 30, 2026) and elegrobart Phase 3 topline data (recently reported positive for REVEAL-1).
• Recent REVEAL-1 results triggered stock volatility, highlighting trial outcomes as major driver.
• Historical earnings misses on EPS but beats on some metrics; stock often reacts sharply to pipeline news.

Earnings Context and Why It Matters

Viridian Therapeutics (VRDN), a clinical-stage biopharmaceutical company targeting thyroid eye disease (TED) and autoimmune conditions, approaches its Q1 2026 earnings amid pivotal regulatory milestones. With no commercial revenue yet, investors scrutinize cash burn, R&D progress, and guidance on potential 2026 launches. The company's veligrotug BLA is under FDA Priority Review with a PDUFA date of June 30, 2026 (Biologics License Application, a regulatory submission for drug approval), while recent positive topline from elegrobart's REVEAL-1 Phase 3 trial in active TED adds momentum but also scrutiny after stock drop on "lackluster" details. In a competitive biotech landscape, this report will signal execution toward commercialization, influencing valuation in a sector sensitive to clinical and regulatory risks.

Earnings Expectations

Consensus estimates peg Q1 2026 (fiscal quarter ended March 31, 2026) EPS at -$1.04 to -$1.20, wider than Q4 2025's reported -$1.08 (missed estimates of -$0.90). Revenue is forecasted at minimal $0.1 million, aligning with collaboration inflows versus Q4's $0.13 million (far below $15.75 million expectations). Investors watch R&D expenses (Q4: $89.2 million, up 24% YoY) and SG&A (Q4: $33.7 million, up 116% on commercial prep). Key metrics include cash updates (end-2025: $874.7 million) and commentary on Q1 REVEAL-1 data integration. Historically, Viridian beat Q3 2025 EPS (-$0.34 vs. -$0.98 expected) on license revenue but missed Q4; stock gained post-Q3 but fell ~37% post-Q4 into March amid pipeline news.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover potential opportunities in biotech like VRDN.

Market Reaction and Investor Sentiment

Heading into Q1 earnings (estimated early May 2026), sentiment is cautious after Q4 miss and 37% YTD stock drop to ~$18.62 (from ~$29.50 post-earnings). Recent REVEAL-1 positive topline sparked volatility, with shares crashing on perceived underwhelming efficacy versus prior IV data, despite meeting endpoints. Analysts maintain Outperform ratings (e.g., Wedbush $44 PT), but risks loom from trial details, PDUFA delays. Options imply ~15-20% move post-report, typical for biotechs.

Forward Outlook and Key Factors to Monitor

Viridian's trajectory hinges on regulatory and clinical catalysts. Post-Q1, track veligrotug commercialization readiness; its BLA targets mid-2026 U.S. launch if approved by June 30 PDUFA, with EMA MAA submitted January 2026. Success could unlock peak sales potential in TED market dominated by Tepezza.

Elegrobart (subcutaneous VRDN-003) advances with REVEAL-1 positive (active TED, Q1 2026 data) and REVEAL-2 (chronic TED, Q2 2026); BLA year-end 2026. Investors should monitor detailed efficacy, safety, and enrollment data for differentiation from intravenous veligrotug.

Pipeline depth includes FcRn inhibitors (VRDN-008 Phase 1 data 2H 2026; VRDN-006 updates) and TSHR program (IND Q4 2026) for TED/Graves’. Cash burn remains key: $875 million supports operations to profitability, bolstered by milestones and potential royalties. Watch expense trends amid headcount growth and manufacturing scale-up.

Industry dynamics like TED prevalence (~1.2M U.S. cases) and competition will shape guidance. Balanced execution could drive re-rating; delays pose downside.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations